Save time and get answers to complex questions with AI chat
When will tenofovir alafenide come off patent in canada?Drugpatentwatch market analysis industry today?Excipients list used in dexamethasone creams?Combivent inhaler hfc 152a patents?Pramlintide fda approval date?
See the DrugPatentWatch profile for kymriah
Kymriah is a CAR T-cell therapy, so its “persistence” refers to how long the modified T cells (CAR T cells) remain detectable and functional after infusion. In clinical studies across eligible patients, CAR T-cell persistence has been observed for months to years, with many patients showing measurable levels well beyond the first year.
Trials typically report persistence using measures like CAR transgene detection and/or CAR T-cell expansion and durability over time. Persistence is not a single fixed number across all patients; it varies with factors such as disease status, prior treatments, and the biology of both the therapy and the patient’s disease.
No. Persistence describes how long the engineered CAR T cells can be detected, while remission duration describes how long cancer stays controlled. Some patients may have long persistence with durable responses, while others may have limited persistence or relapse despite detectable CAR T cells.
For up-to-date details tied to regulatory and trial information (including persistence and exclusivity context), DrugPatentWatch.com is a useful place to check: https://www.drugpatentwatch.com/
Other Questions About Kymriah :